Clinical cancer genome and precision medicine

Annals of Surgical Oncology

Volumn 19, Issue 12, 2012, Pages 3646-3650

  Roukos, Dimitrios H ^a,b   Ku, Chee Seng ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CYCLIN DEPENDENT KINASE 8; CYCLIN DEPENDENT KINASE INHIBITOR; ESTROGEN RECEPTOR; EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VEMURAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BIOINFORMATICS; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CLINICAL DECISION MAKING; COLORECTAL CANCER; COPY NUMBER VARIATION; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; MELANOMA; METASTASIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POINT MUTATION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSCRIPTOMICS; TREATMENT OUTCOME; WHOLE GENOME SEQUENCING;

GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84868115867     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2542-9     Document Type: Review

References (13)

1. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481: 506-10.
2. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol. 2012;795:1-34.
3. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.
4. Baselga J, Campone M, Piccart M, et al. Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-9.
5. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92.
6. Ideker T, Krogan NJ. Differential network biology. Mol Syst Biol. 2012;8:565. doi:10.1038/msb.2011.99.
7. Roukos DH. Differential signaling transduction networks for clinical robustness. Expert Rev Proteomics. 2012;9:111-4.
8. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331:1553-8.
9. Roukos DH. Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn. 2012;12:215-8.
10. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative highthroughput sequencing: a pilot study. Sci Transl Med. 2011;3: 111ra121.
11. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481:389-93.
12. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med. 2012;366:489-91.
13. Roukos DH. Biotechnological, genomics and systems-synthetic biology revolution: Redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices. 2012;9:97-101. doi:10.1586/ERD.11.68.